These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1505332)

  • 21. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus.
    Brink HS; Derkx FH; Boomsma F; Brommer EJ; Schalekamp MA
    Neth J Med; 1993 Aug; 43(1-2):5-12. PubMed ID: 8232694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coagulation activation, fibrinolysis and inhibitors in neonates.
    Koh SC; Cheong YC; Arulkumaran S; Ratnam SS
    Ann Acad Med Singap; 1997 Nov; 26(6):767-71. PubMed ID: 9522977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of compression socks worn during a marathon on hemostatic balance.
    Zaleski AL; Ballard KD; Pescatello LS; Panza GA; Kupchak BR; Dada MR; Roman W; Thompson PD; Taylor BA
    Phys Sportsmed; 2015 Nov; 43(4):336-41. PubMed ID: 26212719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peritoneal fluid and plasma fibrinolytic activity in women with pelvic inflammatory disease.
    Dörr PJ; Brommer EJ; Dooijewaard G; Vemer HM
    Thromb Haemost; 1992 Aug; 68(2):102-5. PubMed ID: 1412151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosis.
    Nguyen G; Horellou MH; Kruithof EK; Conard J; Samama MM
    Blood; 1988 Aug; 72(2):601-5. PubMed ID: 3135860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Tissue-type plasminogen activator and its inhibitor (PAI-1) in plasma in cases of non-insulin-dependent diabetes mellitus (NIDDM)].
    Jokaji H; Asakura H; Saito M; Uotani C; Kumabashiri I; Morishita E; Yamazaki M; Matsuda T
    Nihon Ronen Igakkai Zasshi; 1990 Nov; 27(6):699-705. PubMed ID: 2127812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
    van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
    Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The fibrinolytic system in the hemolytic uremic syndrome: in vivo and in vitro studies.
    van de Kar NC; van Hinsbergh VW; Brommer EJ; Monnens LA
    Pediatr Res; 1994 Aug; 36(2):257-64. PubMed ID: 7970942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibrinolysis and diabetic retinopathy in NIDDM.
    Mansfield MW; Grant PJ
    Diabetes Care; 1995 Dec; 18(12):1577-81. PubMed ID: 8722054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does chronic smoking influence fibrinolytic potential in type 1 diabetes mellitus?
    Simpson AJ; Booth NA; Moore NR; Gray RS
    Diabet Med; 1998 Aug; 15(8):683-7. PubMed ID: 9702473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of prolonged physical exercise on the fibrinolytic system.
    Röcker L; Taenzer M; Drygas WK; Lill H; Heyduck B; Altenkirch HU
    Eur J Appl Physiol Occup Physiol; 1990; 60(6):478-81. PubMed ID: 2118111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physical activity status and adverse age-related differences in coagulation and fibrinolytic factors in women.
    DeSouza CA; Jones PP; Seals DR
    Arterioscler Thromb Vasc Biol; 1998 Mar; 18(3):362-8. PubMed ID: 9514404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noninflammatory joint diseases.
    Kummer JA; Abbink JJ; de Boer JP; Roem D; Nieuwenhuys EJ; Kamp AM; Swaak TJ; Hack CE
    Arthritis Rheum; 1992 Aug; 35(8):884-93. PubMed ID: 1379429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impaired fibrinolytic response to DDAVP in patients with von Willebrand's disease.
    Sultan Y; Loyer F; Venot A
    Nouv Rev Fr Hematol (1978); 1992; 34(1):55-60. PubMed ID: 1523100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of aerobic and anaerobic physical conditioning on fibrinolysis.
    De Paz JA; Lasierra J; Villa JG; Vilades E; Gonzalez-Gallego J
    J Sports Med Phys Fitness; 1995 Dec; 35(4):263-7. PubMed ID: 8776073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of correlation between blood fibrinolysis and the immediate or post-operative blood loss in transurethral resection of the prostate.
    Nielsen JD; Gram J; Fabrin K; Holm-Nielsen A; Jespersen J
    Br J Urol; 1997 Jul; 80(1):105-10. PubMed ID: 9240188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abnormal fibrinolysis in healthy male cigarette smokers: role of plasminogen activator inhibitors.
    Haire WD; Goldsmith JC; Rasmussen J
    Am J Hematol; 1989 May; 31(1):36-40. PubMed ID: 2495714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state.
    Patrassi GM; Sartori MT; Viero ML; Scarano L; Boscaro M; Girolami A
    Blood Coagul Fibrinolysis; 1992 Dec; 3(6):789-93. PubMed ID: 1489900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diurnal variation of the fibrinolytic system.
    Grimaudo V; Hauert J; Bachmann F; Kruithof EK
    Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.